Salmonella enterica serovar Typhi (S. Typhi) causes typhoid fever, a life-threatening human disease. The lack of animal models due to S. Typhi's strict human host specificity has hindered its study and vaccine development. We find that immunodeficient Rag2(-/-) γc(-/-) mice engrafted with human fetal liver hematopoietic stem and progenitor cells are able to support S. Typhi replication and persistent infection. A S. Typhi mutant in a gene required for virulence in humans was unable to replicate in these mice. Another mutant unable to produce typhoid toxin exhibited increased replication, suggesting a role for this toxin in the establishment of persistent infection. Furthermore, infected animals mounted human innate and adaptive immune responses to S. Typhi, resulting in the production of cytokines and pathogen-specific antibodies. We expect that this mouse model will be a useful resource for understanding S. Typhi pathogenesis and for evaluating potential vaccine candidates against typhoid fever.
INTRODUCTION
Typhoid fever remains a global health problem, resulting in more than 200,000 annual deaths, mostly of children in developing countries (Pang et al., 1998; Crump and Mintz, 2010) . Unlike other Salmonella enterica serovars such as S. Typhimurium or S. Enteritidis, which are associated with gastroenteritis (i.e., ''food poisoning'') and can infect a variety of hosts, S. Typhi is an exclusive human pathogen (Parry et al., 2002) . Furthermore, S. Typhi can cause lifelong infections in humans, most often by colonizing the gall bladder. The molecular bases for its host adaptation and ability to cause persistent infection are not known. However, it is believed that a combination of genome degradation and acquisition of new genetic information has conferred on S. Typhi its unique pathogenic properties (Sabbagh et al., 2010) . Although much is known about the pathogenic mechanisms of S. enterica in general and some serovars in particular, remarkably little is known about the unique pathogenic features of S. Typhi. There are currently no effective vaccines against typhoid fever and no vaccines that can be used in young children. The isolation of multidrug-resistant S. Typhi has raised the worrisome possibility of the reemergence of untreatable typhoid fever (Mirza et al., 1996) . Since S. Typhi is restricted to humans, there is no suitable animal model (other than higher primates) in which to study S. Typhi pathogenesis and test potential vaccines. To study typhoid fever pathogenesis, investigators have made use of S. Typhimurium, which in mice carrying a mutation in nramp1 produces a disease that resembles typhoid fever (O'Brien et al., 1980) . Furthermore, S. Typhimurium infection of nramp1 +/+ mice, which are resistant to infection, has been used as a model of persistent infection (Monack et al., 2004) . Although these models have been useful to the understanding of systemic infections by S. enterica in general, they have been of limited value to the study of pathogenic mechanisms specific to S. Typhi. Since S. Typhi is in essence a pathogen of the reticuloendothelial system (Parry et al., 2002; House et al., 2001) it is possible that determinants of host specificity and restriction may reside within the reticuloendothelial system, since this is the most variable compartment across different animal species (Flajnik and Kasahara, 2010; Barreiro and Quintana-Murci, 2010) . Therefore, we sought to investigate the ability of a mouse with a humanized immune system to support infection by S. Typhi. We found that immunodeficient Rag2 À/À gc À/À mice engrafted with human fetal liver hematopoietic stem and progenitor cells support S. Typhi replication and persistent infection. Infected animals mounted a human innate and adaptive immune response to S. Typhi, resulting in the production of cytokines and pathogen-specific antibodies. These results, therefore, indicate that this animal model can be used to study S. Typhi pathogenesis and to evaluate potential vaccine candidates against typhoid fever.
RESULTS AND DISCUSSION
Immunodeficient mice engrafted with human hematopoietic stem and progenitor cells have been used to study human diseases, including immune responses to microbial pathogens (Shultz et al., 2007; Legrand et al., 2006; Manz, 2007 shown that these animals support reconstitution of a functional human immune system (Baenziger et al., 2006; Kuruvilla et al., 2007; Kwant-Mitchell et al., 2009; Yu et al., 2008) . As controls, we used conditioned newborn Rag2 À/À gc À/À mice injected with PBS only ( Figures 1A and 1B ). Average engraftment with human CD45 + hematopoietic cells was 21.3% (range: 3.7%-55.4%) in the animals used in this study ( Figure 1C ). Engrafted mice developed human lymphocytes ( Figures 1D and 1E ) as well as human myeloid cells ( Figures 1F and 1G ). We infected groups of engrafted and control animals with an intraperitoneal dose of wild-type S. Typhi, which in pilot experiments conducted in nonengrafted animals did not result in significant numbers of bacteria recovered from systemic tissues 4 weeks after infection. Neither the control nor the engrafted animals showed any symptoms as a consequence of the infection. However, large numbers of S. Typhi colony-forming units (cfu) were recovered from liver and spleen of engrafted animals at 4 weeks after infection (Figures 2A and 2B ). In contrast, in control animals, bacteria were recovered in much lower numbers (Figures 2A and 2B) . Furthermore, the engrafted group had a higher proportion of animals with larger number of S. Typhi cfu in the gall bladder when compared to the nonengrafted controls, although this difference did not reach statistical significance ( Figure 2C ). This observation may be of interest since the gall bladder is the preferred site of S. Typhi residency in persistently infected humans (Sinnott and Teall, 1987) . We observed mouse-to-mouse variation in the levels of S. Typhi cfu in humanized mice not only between different experiments but also within a given experiment. We hypothesize that this difference may have been due to different levels of engraftment, differences in the lineages of the human cell populations generated in the engrafted animals, differences in the genetic makeup of the human cell donors, or a combination of all these factors. Similar observations have been made in previous studies using humanized mice (Brehm et al., 2010) .
The mouse Nramp1 protein is known to be very important for resistance to S. Typhimurium infection in mice, and nramp1 À/À mice are up to $1000-fold more susceptible to bacterial infection (Skamene et al., 1998) . However, we observed no significant differences between the levels of S. Typhi cfu recovered from engrafted Rag2 Figure S1 ). These results indicate that the Nramp1 status of the mice, which was variable due to the mixed BALB/c 3 129 genetic background, does not influence the outcome of S. Typhi infection of humanized mice, and they are consistent with a previous observation indicating that Nramp1 is not involved in the restriction of S. Typhi replication in mice (O'Brien, 1982) . Although these results are consistent with extensive epidemiological data that have found no association between nramp1 alleles and typhoid fever susceptibility in humans (Dunstan et al., 2001) , it is also possible that mouse cells may not contribute to S. Typhi replication, and hence only the genetic makeup of the engrafted human cells may be relevant for bacterial replication. Indeed, human CD45 + splenocytes containing large numbers of S. Typhi were detected in the spleens of infected animals, indicating that human cells are capable of supporting bacterial replication ( Figure 2D ). In contrast, we did not observe S. Typhi within mouse CD45 + cells (data not shown).
We occasionally observed isolated bacteria in areas of the spleen not stained by either antibody, which may represent extracellular bacteria or nondividing bacteria contained within mouse CD45 À cells. We also observed a specific depletion of human CD45 + cells 4 weeks after infection in the spleens of infected animals ( Figures 2E-2I ), suggesting that bacterial replication may lead to cell death. In contrast, we observed no depletion of mouse CD45 + cells ( Figure 2J ). Taken together, these results suggest that human cells may provide a replicative niche for S. Typhi, although we cannot rule out that human cells only indirectly contribute to bacterial replication. Innate and adaptive immune responses are essential to control S. Typhi infection (Raffatellu et al., 2008; Sztein, 2007 ). Therefore, we tested whether S. Typhi infection resulted in a human innate immune response in the engrafted animals by measuring the levels of several human cytokines in peripheral blood 1 and 4 weeks after infection. Only a few infected animals showed levels of human cytokines above those of control uninfected animals 1 week after infection ( Figure 3A ). In contrast, 4 weeks after infection, a large proportion of the infected animals showed increased levels of the human cytokines TNFa, IL-8, IL-10, IL-12, IFNg, MIP-1a, and IP-10 ( Figure 3A ). These results indicate that engrafted animals were able to mount a human innate immune response to S. Typhi. We also tested whether S. Typhi infection could elicit an acquired human immune response by measuring the levels of S. Typhi-specific antibody responses in the sera of engrafted animals 4 weeks after infection. Significant levels of human antibodies to S. Typhi were detected in $25% of infected animals but not in the uninfected controls ( Figure 3B ). These results indicate that this model could be useful for preclinical testing of S. Typhi vaccine candidates.
A useful animal model should be able to resolve differences between strains of different virulence. Only a limited number of S. Typhi mutant strains have been tested in humans for their virulence properties (Galen et al., 2009) . One of them is the S. Typhi DphoP DphoQ mutant, which has been shown to be avirulent in human volunteer trials and is being considered as a potential vaccine candidate (Hohmann et al., 1996) . PhoP/ PhoQ is a two-component regulatory system that controls the expression of several genes that are critical for virulence (Kato and Groisman, 2008) . We therefore compared the levels of cfu recovered from tissues of engrafted animals infected with either wild-type or an isogeneic DphoP DphoQ mutant 4 weeks after infection. We found that the levels of wild-type S. Typhi were significantly higher than those of the DphoP DphoQ mutant, and contrary to wild-type, the mutant strain was either not detected in tissues or was recovered in much lower numbers (Figures 4A and 4B) . Consistent with its poor replication, the DphoP DphoQ mutant did not stimulate a human immune response in the engrafted animals ( Figure 3B ). Typhoid toxin is a recently identified potential virulence factor of S. Typhi (Haghjoo and Galá n, 2004; Spanò et al., 2008) . Exclusively produced by S. Typhi and S. Paratyphi, this toxin is composed of one ''B'' subunit, known as PltB, and two active subunits, known as CdtB and PltA, which have nuclease and the ADP-ribosyl transferase activities. Although it is known that this toxin is Cell Host & Microbe exclusively produced by intracellularly located bacteria (Haghjoo and Galá n, 2004) , the role of typhoid toxin in S. Typhi pathogenesis and infection is unknown. We therefore tested the virulence of a S. Typhi DpltB mutant strain. PltB is essential for toxin delivery, so a strain lacking this subunit is unable to intoxicate cultured epithelial cells (Spanò et al., 2008) . Surprisingly, we found that this mutant strain exhibited increased ability to replicate in the humanized mouse model. Significantly higher cfu of this mutant were detected in the liver and spleen of humanized mice. These results suggest the possibility that typhoid toxin may contribute to the establishment of persistent infection, perhaps by slowing down S. Typhi replication in infected tissues.
Additional studies will be required to understand the role of typhoid toxin in S. Typhi infection. Taken together, these results indicate that this model can be used to evaluate the in vivo replication of S. Typhi mutant strains and could therefore be useful in the preclinical evaluation of virulence-attenuated vaccine candidates. We have shown here that an immunodeficient mouse engrafted with human hematopoietic stem and progenitor cells can support the replication of S. Typhi and can serve as a model to study this human-specific pathogen. Humanizing the immune system of the mouse effectively relieved the potent host-specificity barrier that blocks S. Typhi replication in this species and Typhi within human cells in the engrafted animals. However, it is also possible that the human cells help S. Typhi to overcome some (yet unknown) ''bottleneck'' that prevents the progression of S. Typhi infection. Our results have shown that S. Typhi infection in humanized mice is very different from that of S. Typhimurium in conventional mice. This is highlighted by the observation that the Nramp1 protein, which plays a dominant role in conferring resistance to S. Typhimurium, did not influence the susceptibility of humanized mice to S. Typhi. Infection of humanized mice did not lead to acute lethal infection (i.e., murine typhoid), although it led to persistent infection, a very poorly understood aspect of S. Typhi pathogenesis. It is not clear why humanized animals did not develop symptoms of systemic infection despite the presence of a large number of bacteria in various tissues.
However, it is likely that the inability of the human cytokines to effectively act on mouse tissues (Libert et al., 1990; Manz, 2007; Schoenhaut et al., 1992) may prevent the development of systemic pathology. Future improvements on this mouse model may allow the modeling of systemic pathology and may increase the consistency of the engrafted animals to support infection and immune responses. The detailed study of S. Typhi infection in the humanized mouse model described here may lead to a better understanding of several aspects of human S. Typhi pathogenesis. One of the most significant hurdles for the development of S. Typhi vaccines has been the absence of a convenient animal model that can be used to test virulenceattenuated mutants and evaluate their vaccine potential. It is known that immunization or even virulence studies in conventional mice often do not translate well into humans. The model described here may therefore greatly facilitate the development and preclinical testing of typhoid fever therapeutic and prevention strategies. (Traggiai et al., 2004) . Control mice were injected with PBS only. Engraftment with human hematopoietic cells was determined 8-14 weeks posttransplantation by retro-orbital bleeding and flow cytometry as described below. Mice used for experiments had blood engraftment levels of R15% hCD45 + cells. Mice were maintained under specific-pathogen-free conditions and received prophylactic antibiotics (Sulfatrim) in the drinking water to prevent opportunistic infections until 2 weeks prior to S. Typhi infection. All animal work was approved by the Yale University Institutional Animal Care and Use Committee (IACUC) and conducted in accordance with IACUC regulations.
Cell Host & Microbe

Flow Cytometry
Cell suspensions were prepared from bone marrow, spleen, and blood of mice 10-14 weeks posttransplantation. Lysis of RBC was performed using ACK lysis buffer (Lonza, Basel). Samples were then stained with fluorochromelabeled monoclonal antibodies (mAbs) against mouse and human cell surface antigens. The following mAbs were used: (1) anti-human: CD3 (UCHT1), CD11c (B-ly6), CD14 (MoP9), CD19 (HIB19), CD33 (WM53), CD45 (HI30 and 2D1), CD66 (B1.1); (2) anti-mouse: CD45 (30-F11). CD45 (30-F11) mAb was from eBioscience (San Diego, CA). All other mAbs were from BD Biosciences (San Jose, CA). Samples were analyzed on a FACSCalibur or LSR II flow cytometer (BD Biosciences).
Bacterial Strains, Media, and Growth Conditions
The wild-type S. enterica serovar Typhi strain ISP2825 and its isogenic DpltB mutant have been described previously (Galá n and Curtiss, 1991; Spanò et al., 2008) . A mutant strain carrying an in-frame deletion in DphoP DphoQ in the chromosome was constructed by standard recombinant DNA and allelic exchange procedures as previously described (Kaniga et al., 1994) . S. Typhi strains were grown overnight at 37 C in 2 ml LB broth. For mouse experiments, overnight cultures of bacteria were freshly inoculated at a dilution of 1:50 in LB broth containing 0.3 M NaCl and grown at 37 C to an OD 600 of $0.8. Indicated numbers of bacteria were prepared in buffered saline with gelatin (BSG) (8.5 g NaCl, 0.3 g KH 2 PO 4 , 0.6 g Na 2 HPO 4 , 0.1 g gelatin in 1000 ml distilled water [pH 7.0]) for mouse experiments. All S. Typhi strains used in these studies were verified to be Vi antigen positive.
Bacterial Infections and Colony-Forming Units Assay
All animal experiments were conducted according to protocols approved by Yale University's Institutional Animal Care and Use Committee. Groups of control and humanized 13-to 16-week-old mice were infected intraperitoneally with either 10 4 or 10 5 wild-type S. Typhi or the isogenic DphoP DphoQ or DpltB mutant strains in 100 ml of BSG. Infected animals were sacrificed and organs were harvested at 5, 11, 21, and 28 days postinfection to perform in vivo cfu assays. Spleens, livers, and gall bladders were aseptically removed and mechanically homogenized in 3 ml (for spleens and gall bladders) or 5 ml (for livers) sterile PBS containing 0.05% sodium deoxycholate. Bacterial loads were determined by plating 10-fold serial dilutions of homogenates on LB agar plates and incubated overnight at 37 C. Colonies were counted and the number of total cfu recovered was calculated.
Immunofluorescence of Spleen Sections
Control and humanized 12-to 14-week-old mice were infected intraperitoneally with 10 6 S. Typhi in 100 ml BSG. Five days after infection, spleens were aseptically removed, fixed in 3.7% formaldehyde overnight, paraffin embedded, and cut 5 mm thick. Tissue sections were pretreated at 95 C for 20 min in 10 mM citrate buffer (pH 6.0) to retrieve the epitope and followed by 30 min incubation at RT with the primary antibodies. Monoclonal mouse anti-human CD45, leukocyte common antigen ( mounted using a mounting reagent (Vector Laboratories; Burlingame, CA; H1200).
Peripheral Blood Leukocyte Preparation, Splenocyte Preparation, Immunostaining, and FACS Analysis Peripheral blood of uninfected and infected humanized mice was collected into heparinized tubes. In order to remove RBCs, $100 ml heparinized blood was incubated with 1 ml ACK lysis buffer (Lonza) for 5 min on ice, washed with 2 ml PBS, and centrifuged to collect peripheral blood leukocytes (PBLs). This RBC-lysis step was repeated once more, and PBLs were immediately processed for an immunostaining as described below. Spleens of uninfected and infected humanized mice were aseptically harvested, mechanically homogenized, and filtered using a nylon mesh to obtain single-cell suspensions. RBCs were lysed by incubating them with 1 ml ACK lysis buffer. After washing, cells were immediately incubated for 30 min on ice with 100 ml of an antibody cocktail containing anti-mouse CD45 (30-F11; eBioscience) and anti-human CD45 (HI30 and 2D1; BD Biosciences), CD3 (UCHT1; BD Biosciences), and CD19 (HIB19; BD Biosciences). The cells were then washed with 2 ml FACS buffer (0.16% BSA/0.1% NaN 3 /PBS), resuspended in 100 ml FACS fix buffer (1% FCS/1% Formaldehyde/PBS), kept at 4 C overnight, and used for FACS analyses. Total splenocyte numbers were determined by cell counting using a hemocytometer.
Human Cytokine/Chemokine Measurement Human cytokine/chemokine concentration in the sera of control and humanized animals were measured using a human cytokines/chemokines/growth factors multiplex kit (Millipore; Billerica, MA) according to the manufacturer's protocol. The following human cytokines were assayed: Eotaxin, G-CSF, GM-CSF, IFN-a2, IFN-g, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL-17, IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIP-1a, MIP-1b, TNF-a, and TNF-b. Only human cytokines that showed a significant elevation in serum after S. Typhi infection are shown in Figure 3 . The other cytokines were either not detected or detected in a small subset of infected animals.
Measurement of Human S. Typhi-Specific Antibody Responses Human S. Typhi-specific antibody levels in the sera of infected humanized mice were examined using a direct ELISA. ELISA plates were coated with a S. Typhi total cell lysate prepared as follows: S. Typhi was cultured in 50 ml LB broth, heat killed at 70 C for 20 min, centrifuged, and resuspended in 50 mM Tris buffer (pH 8.0) containing 1% Triton X-100 and a protease inhibitor cocktail (Roche, Basel). The bacterial cells were then sonicated, and unbroken cells were removed by centrifugation. 96-well plates (Maxisorp, Nunc; Rochester, NY) were coated with 30 mg bacterial cell lysates in 100 ml plate-coating buffer (0.5 M carbonate-bicarbonate buffer [pH 9.6]) (per well) and incubated overnight at 4 C. Wells were washed with PBS containing 0.05% Tween 20 and blocked with PBS containing 1% BSA for 1 hr at 37 C.
Two-fold serial dilution of the sera contained in 50 ml PBS/0.05% Tween 20/ 0.5% BSA was added into each well and incubated for 2 hr at 37 C. After washing, bound antibodies were detected with HRP-conjugated anti-human immunoglobulin (IgM, IgG, and IgA; SouthernBiotech; Birmingham, AL) at a 1:4000 dilution in PBS/0.05% Tween 20/0.5% BSA. Wells were then incubated with a HRP substrate, tetramethylbenzidine (TMB; Sigma, St. Louis), for 10-30 min, and the reaction was stopped by addition of 100 ml of 1M H 3 PO 4 . Relative serum antibody levels were determined by standard endpoint ELISA titration.
nramp1 Genotyping Tail biopsies from sacrificed animals were incubated in 500 ml DNA digestion buffer (50 mM Tris-HCl [pH 8.0], 100 mM EDTA [pH 8.0], 100 mM NaCl, 1% SDS, and 0.5 mg/ml protease K) overnight at 53 C with gentle shaking. The following day, supernatants were taken after microcentrifugation at maximum speed for 10 min. One volume of isopropanol was mixed with the supernatants to precipitate DNA. DNA pellet was obtained by microcentrifugation, resuspended in 50 ml TE buffer, and used for nramp1 PCR amplification. A 514 bp fragment of the nramp1 gene was amplified by PCR using primers 5 0 -AAGTG ACATCTCGCCATAGGTGCC-3 0 (forward) and 5 0 -TTCTCTCACCATAGTTATC CAAGAAG-3 0 (reverse). The purified PCR product was then sequenced using the primer 5 0 -CCCCCATCTATGTTATCACCC-3 0 .
Statistics
Statistical analysis was conducted with the two-tailed Mann-Whitney test.
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